ClinicalTrials.gg
No longer availableNCT03433131Updated Aug 28, 2019

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

An expanded access record providing Pitolisant in Narcolepsy Without Cataplexy and Narcolepsy With Cataplexy, sponsored by Harmony Biosciences Management, Inc.. No longer available at 71 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Expanded access

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.

Other kind
Only one
of the 85
Registered
29th of 85
by date
Lead sponsor
4 of 85
Harmony Biosciences Management, Inc.

Among the 85 studies in Narcolepsy with a site in United States, this one is the only one of another kind, and was the 29th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Narcolepsy with a site in United States, or all of them as a file.
02

Study summary

This EAP will be open to provide access to treatment with pitolisant while a U.S. New Drug Application (NDA) is being prepared and submitted for review for marketing approval. This program will be open to adult patients in the U.S. with Excessive Daytime Sleepiness (EDS) associated with narcolepsy, with or without cataplexy. Pitolisant will be made available through treating physicians participating in the program.

03

Conditions studied

  • Narcolepsy Without Cataplexy
  • Narcolepsy With Cataplexy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the treating physician, the patient is capable of understanding and complying with protocol and program requirements, oral drug administration and care instructions.
  2. The patient or, when applicable, the patient's legally acceptable representative, signs and dates a written, ICF and any required privacy authorization prior to the initiation of any program procedures.
  3. Men or women, 18 years of age and over.
  4. Patients with a diagnosis of narcolepsy with or without cataplexy according to the ICSD or DSM criteria at the time of diagnosis.
  5. Patients should be free of prohibited treatments or have discontinued them for at least 7 days prior to the start of treatments.
  6. Women of must have a negative serum pregnancy test performed at the screening visit.
  7. Due to the effectiveness of hormonal potentially being reduced when used with pitolisant, alternative or concomitant barrier methods of contraception are required for patients taking hormonal contraceptives (e.g., ethinyl estradiol) when taking pitolisant and for at least 21 days after discontinuation of pitolisant treatment.

Exclusion criteria

Exclusion Criteria:

  1. The patient has severe hepatic impairment ( C).
  2. The patient is a woman who is breastfeeding or plans to breastfeed during their participation.
  3. The patient has, in the judgment of the treating physician, a history or current medical condition that could affect safety or poses an additional risk to the patient by their participation in the program.
  4. The patient is at high risk for suicide defined as a suicide attempt within the past year, significant risk determined by the investigator interview, or use of the Columbia Suicide Severity Rating Scale (C-SSRS).
  5. The patient has a history of or allergic reaction to pitolisant or any inactive ingredient of the formulation.
  6. Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in (DSM-V).
  7. Patients with a known history of long syndrome (e.g. syncope or arrhythmia) or any significant history of a serious abnormality of the (e.g. recent myocardial infarction), or QTc Fridericia higher than 450 ms for male and 470 ms for female (electrocardiogram Fridericia's corrected QT interval = QT / 3√ RR).
  8. Significant abnormality in the physical examination or clinical laboratory results.
  9. Prior severe adverse reactions to CNS stimulants.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

06

Where to request access

71 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • CPC
    Cullman, Alabama 35058, United States
  • Xenoscience
    Phoenix, Arizona 85004-1150, United States
  • Xenoscience
    Phoenix, Arizona 85004, United States
  • Foothills Neurology
    Phoenix, Arizona 85048, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Sleep Medicine Specialists of California
    San Ramon, California 94583, United States
  • Santa Monica Sleep Disorders Center
    Santa Monica, California 90404, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Colorado Sleep Institute
    Boulder, Colorado 80301, United States
  • Norwalk Hospital Sleep Disorders Center
    Norwalk, Connecticut 06850, United States
  • Clinical Neurosciences fo Tampa Bay
    Clearwater, Florida 33756, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Sleep Medicine Specialists of South Florida, PA
    Miami, Florida 33126, United States
  • Child Lung, Asthma Sleep Specialists
    Winter Park, Florida 32789, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • NeuroTrials Research Center
    Atlanta, Georgia 30342, United States
  • The Neurological Center of North Georgia
    Gainesville, Georgia 30501, United States
  • Critical Healthcare Decisions
    Savannah, Georgia 31419, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60637, United States
  • NorthShore Uni HealthSys-Glenbrook Hospital
    Glenview, Illinois 60026, United States
  • Northshore Sleep Medicine
    Northbrook, Illinois 60062, United States
  • Indiana Internal Medicine Consultants
    Greenwood, Indiana 46143, United States
  • The University of Kansas Health System
    Fairway, Kansas 66205, United States
  • Norton Pulmonary Specialists
    Louisville, Kentucky 40218, United States
  • Maine Medical Partners - Neurology
    Scarborough, Maine 04074, United States
  • The Center for Sleep and Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • The University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Bronson Sleep Health
    Portage, Michigan 49024, United States
  • Alliance Health Shelby Family Medicine
    Shelby, Michigan 48317, United States
  • Fairview Health Services
    Brooklyn Park, Minnesota 55443, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • St. Lukes Hospital, Sleep Medicine
    Chesterfield, Missouri 63017, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Norwell Health
    New Hyde Park, New York 11042, United States
  • NYU-FGP Comphrenhensive Epilepsy Center-Sleep Center
    New York, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • Unity Sleep Disorders Center
    Rochester, New York 14618, United States
  • University of Rochester Sleep Center
    Rochester, New York 35058, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Excel Psychiatric Associates, PA
    Huntersville, North Carolina 28078, United States
  • Raleigh Neurology Assoc., PA
    Raleigh, North Carolina 27607, United States
  • Neurology & Neuroscience Associates, Inc.
    Akron, Ohio 44320, United States
  • Intrepid Research, LLC
    Cincinnati, Ohio 45245, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017, United States
  • Oklahoma Heart Institute
    Tulsa, Oklahoma 74104, United States
  • Oklahoma Heart Institute
    Tulsa, Oklahoma 74133, United States
  • Legacy Medical Group Sleep Medicine
    Portland, Oregon 97210, United States
  • Collegeville Family Practice
    Berwyn, Pennsylvania 19426, United States
  • Paoli Sleep Center
    Paoli, Pennsylvania 19301, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Maria J. Sunseri, MD, LLC
    Pittsburgh, Pennsylvania 15224, United States
  • Abington Neurological Associates
    Willow Grove, Pennsylvania 19090, United States
  • Respitory Specialists
    Wyomissing, Pennsylvania 19610, United States
  • Brown Medicine/Rhode Island Hospital
    West Warwick, Rhode Island 02893, United States
  • Bogan Sleep Consultants
    Columbia, South Carolina 29201, United States
  • Sleep Medicine Associates of Texas
    Dallas, Texas 75231, United States
  • Houston Neurology & Sleep Center
    Houston, Texas 77063, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Comprehensive Sleep Medicine Associates
    Sugar Land, Texas 77478, United States
  • Chalottesville Neurology and Sleep Medicine
    Charlottesville, Virginia 22911, United States
  • Children's Hospital of The King's Daughters
    Norfolk, Virginia 23507, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • Stultz Sleep and Behavioral Health
    Barboursville, West Virginia 25504, United States
  • Medical College of Wisonsin
    Milwaukee, Wisconsin 53226, United States
07

References and documents

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03433131
Responsible party
Sponsor
First posted
Feb 14, 2018
Last update
Aug 28, 2019

Study contacts

Michael Thorpy, MD
principal investigator · Albert Einstein College of Medicine
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion